Cefazolin sodium
Based on 13 publication(s) in Google Scholar
Cefazolin sodium is a first-generation cephalosporin antibiotic and can be used in varieties of bacterial infections research. Cefazolin sodium has anti-inflammatory effect and can attenuate post-operative cognitive dysfunction (POCD).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.45%
- CAS No.: 27164-46-1
- 화학식: C14H13N8NaO4S3
- 분자량:476.49
-
보관:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Antibacterial Compound Library
HY-L049
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Cefazolin sodium
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Nat Commun. 2022 Mar 2;13(1):1116. [Abstract]
- J Exp Med. 2026 Mar 2;223(3):e20241287. [Abstract]
- ACS Environ Au. 2025 Aug 5;5(6):573-582. [Abstract]
- Anal Chem. 2025 Jun 3;97(21):11099-11109. [Abstract]
- Emerg Microbes Infect. 2024 Dec;13(1):2321981. [Abstract]
- mSystems. 2023 Dec 21;8(6):e0102623. [Abstract]
- ACS Omega. 2022 Mar 3;7(10):9004-9014. [Abstract]
- Front Aging Neurosci. 2021 Oct 13;13:748637. [Abstract]
- iScience. 2022 Jan 5;25(2):103731. [Abstract]
- Infect Drug Resist. 2026 May 8;19.
- Diagn Microbiol Infect Dis. 2026 Feb;114(2):117181. [Abstract]
- bioRxiv. 2024 May 10.
All Antibiotic Isoforms
More
Biological Activity
|
β-lactam |
Cefazolin sodium (0-300 μg/ml; 6 or 24 h) has a direct anti-inflammatory effect on C8-B4 cells stimulated by lipopolysaccharide[2].
Cefazolin sodium (0-400 μM; 72 h) treatment inhibits IL-2, IL-4 and IL-15-induced cell proliferation[3].
Cefazolin sodium (0-400 μM; 30 min) treatment inhibits IL-2, IL-4, IL-15 and IL-21-stimulated JAK3 phosphorylation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:C8-B4 cells
-
Concentration:0, 50, 100, 150, 200, 250, or 300 μg/ml
-
Incubation Time:6 or 24 hours
-
Result:Inhibited the increase of IL-1β at all doses, but inhibited the increase of IL-6 only at 200 μg/ml.
-
Cell Line:PBMC, and TF-1 cells
-
Concentration:0, 100, 200, and 400 μM
-
Incubation Time:72 hours
-
Result:Reduced IL-2, IL-4 and IL-15-induced cell proliferation, suggested that Cefazolin interferes not only with IL-15Rα, but also with IL-2/IL-15Rβ and/or γc.
-
Cell Line:PBMC, NK-92, and TF-1 cells
-
Concentration:0, 100, 200, and 400 μM
-
Incubation Time:30 min
-
Result:Diminished the phosphorylation of JAK3 in response to the cytokine treatment, concluded suppressing signal transduction by γc receptors.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6- to 8-week-old male CD-1 mice underwent clinical exploratory laparotomy[2]
-
Dosage:300-500 mg/kg
-
Administration:Subcutaneous injection; 300-500 mg/kg; once daily; 5 days
-
Result:Attenuated learning and memory dysfunction induced by the surgery.
Chemical Information
-
CAS No. 27164-46-1
-
Appearance Solid
-
분자량 476.49
-
화학식 C14H13N8NaO4S3
-
Color White to off-white
-
SMILES
O=C(C(N12)=C(CSC3=NN=C(C)S3)CS[C@]2([H])[C@H](NC(CN4N=NN=C4)=O)C1=O)O[Na]
-
Synonyms
Cephazolin sodium
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (13)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Nat Commun
Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]2022 Mar 2;13(1):1116. PMID: 35236849 -
J Exp Med
2026 Mar 2;223(3):e20241287. PMID: 41400657 -
ACS Environ Au
Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]2025 Aug 5;5(6):573-582. PMID: 41277996 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Emerg Microbes Infect
AMXT-1501 targets membrane phospholipids against Gram-positive and -negative multidrug-resistant bacteria. [Abstract]2024 Dec;13(1):2321981. PMID: 38422452 -
mSystems
2023 Dec 21;8(6):e0102623. PMID: 38047647 -
ACS Omega
Lapatinib Acts against Biofilm Formation and the Hemolytic Activity of Staphylococcus aureus. [Abstract]2022 Mar 3;7(10):9004-9014. PMID: 35309438 -
Front Aging Neurosci
Cefazolin Improves Anesthesia and Surgery-Induced Cognitive Impairments by Modulating Blood-Brain Barrier Function, Gut Bacteria and Short Chain Fatty Acids. [Abstract]2021 Oct 13;13:748637. PMID: 34720997 -
iScience
2022 Jan 5;25(2):103731. PMID: 35098100 -
-
Diagn Microbiol Infect Dis
2026 Feb;114(2):117181. PMID: 41205476 -
용액&용해도
H2O : ≥ 100 mg/mL (209.87 mM)
DMSO : 100 mg/mL (209.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.25 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.25 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (209.87 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
순도&문서
-
Data Sheet (279 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Handling Instructions (2659 KB)
References
[1]. R Quintiliani, et al. Cefazolin. Ann Intern Med. 1978 Nov;89(5 Pt 1):650-6. [Content Brief]
[2]. Peng Liang, et al. Perioperative use of cefazolin ameliorates postoperative cognitive dysfunction but induces gut inflammation in mice. J Neuroinflammation. 2018 Aug 22;15(1):235. [Content Brief]
[3]. Barbara Żyżyńska-Granica, et al. The anti-inflammatory potential of cefazolin as common gamma chain cytokine inhibitor. Sci Rep. 2020 Feb 19;10(1):2886. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.0987 mL | 10.4934 mL | 20.9868 mL | 52.4670 mL |
| 5 mM | 0.4197 mL | 2.0987 mL | 4.1974 mL | 10.4934 mL | |
| 10 mM | 0.2099 mL | 1.0493 mL | 2.0987 mL | 5.2467 mL | |
| 15 mM | 0.1399 mL | 0.6996 mL | 1.3991 mL | 3.4978 mL | |
| 20 mM | 0.1049 mL | 0.5247 mL | 1.0493 mL | 2.6233 mL | |
| 25 mM | 0.0839 mL | 0.4197 mL | 0.8395 mL | 2.0987 mL | |
| 30 mM | 0.0700 mL | 0.3498 mL | 0.6996 mL | 1.7489 mL | |
| 40 mM | 0.0525 mL | 0.2623 mL | 0.5247 mL | 1.3117 mL | |
| 50 mM | 0.0420 mL | 0.2099 mL | 0.4197 mL | 1.0493 mL | |
| 60 mM | 0.0350 mL | 0.1749 mL | 0.3498 mL | 0.8744 mL | |
| 80 mM | 0.0262 mL | 0.1312 mL | 0.2623 mL | 0.6558 mL | |
| 100 mM | 0.0210 mL | 0.1049 mL | 0.2099 mL | 0.5247 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Cefazolin sodium Related Classifications
HY-B1078 Related Classifications
Powered by Bioz